Radiosensitization mediated by a transfected anti-ERBB-2 single-chain antibody in vitro and in vivo

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 817-822

  Stackhouse, Murray A ^a   Buchsbaum, Donald J ^a   Grizzle, William E ^b   Bright, Sheila J ^a   Olsen, Christine C ^a   Kancharla, Sreekanth ^a   Mayo, Matthew S ^c   Curiel, David T ^c,d  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Gene therapy; p185(erbB 2); Radiation therapy; Radiosensitization; Single chain antibody

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB 2 SINGLE CHAIN ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN P185; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; CANCER RADIOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY;

ANIMALS; ANTIBODIES; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, ERBB-2; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 0031772093     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00330-7     Document Type: Conference Paper

References (29)

1. Waldman T., Zhang Y., Dilehay L., Yu J., Kinzler K., Vogelstein B., Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nature Med. 3:1997;1034-1036.
2. Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 57:1997;4703-4706.
3. Yarden Y., Ullrich A. Growth factor receptor tyrosine kinases. Ann Rev Biochem. 57:1988;443-478.
4. Hudziak R.M., Schlessinger J., Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA. 84:1987;7159-7163.
5. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54:1988;105-115.
6. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
7. Noguchi M., Murakami M., Bennett W., Lupu R., Hui F., Harris C.C., Gerwin B.I. Biological consequences of overexpression of a transfected c-erbB-2 in immortalized human bronchial epithelial cells. Cancer Res. 53:1993;2035-2043.
8. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst. 86:1994;1140-1145.
9. Hynes N.E. Amplification and overexpression of the erbB-2 gene in human tumors its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy . Semin Cancer Biol. 4:1993;19-26.
10. Giovanella B.C., Vardeman D.M., Williams L.J., Taylor D.J., de Ipolyi P.D., Greeff P.J., Stehlin J.S., Ullrich A., Cailleau R., Slamon D.J., et al. Heterotransplantation of human breast carcinomas in nude mice Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene . Int J Cancer. 47:1991;66-71.
11. Deshane J., Loechel F., Conry R.M., Siegal G.P., King C.R., Curiel D.T. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. 1:1994;332-337.
12. Beerli R.R., Winfried W., Hynes N.E. Intracellular expression of single chain antibodies reverts erbB-2 transformation. J Biol Chem. 269:1994;23931-23936.
13. Deshane J., Siegel G.P., Alvarez R.D., Wang M., Feng M., Cabrera G., Liu T., Kay M., Curiel D.T. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest. 96:1995;2980-2989.
14. Deshane J., Cabrera G., Grim J.E., Siegel G.P., Pike J., Alvarez R.D., Curiel D.T. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol. 59:1995;8-14.
15. Deshane J., Grim J., Loechel S., Siegal G.P., Alvarez R.D., Curiel D.T. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther. 3:1996;89-98.
16. Barnes M.N., Deshane J.S., Siegal G.P., Alvarez R.D., Curiel D.T. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin Cancer Res. 2:1996;1089-1095.
17. Barnes MN, Wang M, Deshane J, Vanderkwaak TJ, Siegal GP, Alvarez RD, Curiel DT. In vivo efficacy of an anti-ErbB-2 intracellular single chain antibody in combination with cisplatin in a murine model of ovarian carcinoma. Gene Ther Submitted.
18. Myers R.B., Srivastava S., Oelschlager D.K., Brown D., Grizzle W.E. Expression of nm23-H1 in prostatic intraepithelial neoplasia and adenocarcinoma. Human Pathol. 27:1996;1021-1024.
19. Collet D. Modelling survival data in medical research. 1994;Chapman and Hall, London.
20. Daniel W.W. Applied nonparametric statistics. 1978;Hougton Mifflin Company, Boston.
21. Drebin J.A., Link V.C., Greene M.I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene. 2:1988;387-394.
22. Fendly B.M., Winget M., Hudziak R.M., Lipari M.T., Napier M.A., Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50:1990;1550-1558.
23. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:1992;4285-4289.
24. Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA. 92:1995;3353-3357.
25. Arteaga C.L., Winnier A.R., Poirier M.C., Lopez-Larraza D.M., Shawver L.K., Hurd S.D., Stewart S.J. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair . Cancer Res. 54:1994;3758-3765.
26. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 9:1994;1829-1838.
27. Wollman R., Yahalom J., Maxy R., Pinto J., Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 30:1994;91-98.
28. Saleh M., Buchsbaum D., Meredith R., Lalisan D. Jr, Wheeler R. In vitro and in vivo evaluation of the cytotoxicity of radiation combined with chimeric monoclonal antibody to the epidermal growth factor receptor. Proc Am Assoc Cancer Res. 37:1996;612. (Abstr.).
29. Lamb J.R., Friend S.H. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes . Nature Med. 3:1997;962-963.